Search research articles
Contact Us
Filters
Showing results (31-40 of 358) with videos related to
Page
of 36
Sort By:
Hematology/Oncology Clinics of North America
|
January 6, 2024
Measurable Residual Disease and Decision-Making in Multiple Myeloma
Benjamin A Derman, Rafael Fonseca
Clinical Lymphoma & Myeloma
|
October 16, 2008
Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial
Rafael Fonseca, S Vincent Rajkumar
Cancers
|
October 16, 2024
Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies
Kevin Guanwen Shim, Rafael Fonseca
Pharmacogenomics
|
September 7, 2005
Genomics in multiple myeloma: biology and clinical implications
Wee J Chng, Rafael Fonseca
Molecular Cancer Therapeutics
|
March 17, 2007
Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach
Rafael Fonseca, A Keith Stewart
Expert Review of Molecular Diagnostics
|
July 11, 2007
Review of molecular diagnostics in multiple myeloma
A Keith Stewart, Rafael Fonseca
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
March 25, 2020
Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard
Rafael Fonseca, Miguel Gonzalez-Velez
BMC Pediatrics
|
February 12, 2017
The association between vancomycin trough concentrations and acute kidney injury in the neonatal intensive care unit
Vidit Bhargava, Michael Malloy, Rafael Fonseca
Blood Cancer Journal
|
January 15, 2024
Translocation t(14;16) in multiple myeloma: gangster or just part of the gang?
Hira Mian, Martin Kaiser, Rafael Fonseca
Clinical Lymphoma, Myeloma & Leukemia
|
July 24, 2014
Amitriptyline-induced agranulocytosis with bone marrow confirmation
Natalya Azadeh, Katalin Kelemen, Rafael Fonseca
Page
of 36
Search research articles
Search
Showing results (31-40 of 358) with videos related to
Sort By:
Page
of 36
Hematology/Oncology Clinics of North America
|
January 6, 2024
Measurable Residual Disease and Decision-Making in Multiple Myeloma
Benjamin A Derman, Rafael Fonseca
Clinical Lymphoma & Myeloma
|
October 16, 2008
Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial
Rafael Fonseca, S Vincent Rajkumar
Cancers
|
October 16, 2024
Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies
Kevin Guanwen Shim, Rafael Fonseca
Pharmacogenomics
|
September 7, 2005
Genomics in multiple myeloma: biology and clinical implications
Wee J Chng, Rafael Fonseca
Molecular Cancer Therapeutics
|
March 17, 2007
Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach
Rafael Fonseca, A Keith Stewart
Expert Review of Molecular Diagnostics
|
July 11, 2007
Review of molecular diagnostics in multiple myeloma
A Keith Stewart, Rafael Fonseca
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
March 25, 2020
Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard
Rafael Fonseca, Miguel Gonzalez-Velez
BMC Pediatrics
|
February 12, 2017
The association between vancomycin trough concentrations and acute kidney injury in the neonatal intensive care unit
Vidit Bhargava, Michael Malloy, Rafael Fonseca
Blood Cancer Journal
|
January 15, 2024
Translocation t(14;16) in multiple myeloma: gangster or just part of the gang?
Hira Mian, Martin Kaiser, Rafael Fonseca
Clinical Lymphoma, Myeloma & Leukemia
|
July 24, 2014
Amitriptyline-induced agranulocytosis with bone marrow confirmation
Natalya Azadeh, Katalin Kelemen, Rafael Fonseca
Page
of 36